Everything below concerns GLP-1 receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
On 20 January 2001 the Indian Space Research Organisation (ISRO) conducted a balloon flight from Hyderabad, India to collect stratospheric dust from a height of 41 km (135,000 ft) with a view to testing for the presence of living cells. The collaborators on this project included a team of UK scientists led by Wickramasinghe. In a paper presented at a SPIE conference in San Diego in 2002 the detection of evidence for viable microorganisms from 41 km above the Earth's surface was presented. However, the experiment did not present evidence as to whether the findings are incoming microbes from space rather than microbes carried up to 41 km from the surface of the Earth. In 2005 the ISRO group carried out a second stratospheric sampling experiment from 41 km altitude and reported the isolation of three new species of bacteria including one that they named Janibacter hoylei sp.nov. in honour of Fred Hoyle. However, these facts do not prove that bacteria on Earth originated in the cosmic environment. Samplings of the stratosphere have also been carried out by Yang et al. (2005, 2009). During the experiment strains of highly radiation-resistant Deinococcus bacterium were detected at heights up to 35 km. Nevertheless, these authors have abstained from linking these discoveries to panspermia. Wickramasinghe was also involved in coordinating analyses of the red rain in Kerala in collaborations with Godfrey Louis.
=== Investigations === Diabetic ketoacidosis may be diagnosed when the combination of hyperglycemia (high blood sugars), ketones in the blood or on urinalysis and acidosis are demonstrated. In about 10% of cases the blood sugar is not significantly elevated ("euglycemic diabetic ketoacidosis"). A pH measurement is performed to detect acidosis. Blood from a vein is adequate, as there is little difference between the arterial and the venous pH; arterial samples are only required if there are concerns about oxygen levels. Ketones can be measured in the urine (acetoacetate) and blood (β-hydroxybutyrate). When compared with urine acetoacetate testing, capillary blood β-hydroxybutyrate determination can reduce the need for admission, shorten the duration of hospital admission and potentially reduce the costs of hospital care. At very high levels, capillary blood ketone measurement becomes imprecise. In addition to the above, blood samples are usually taken to measure urea and creatinine (measures of kidney function, which may be impaired in DKA as a result of dehydration) and electrolytes. Furthermore, markers of infection (complete blood count, C-reactive protein) and acute pancreatitis (amylase and lipase) may be measured. Given the need to exclude infection, chest radiography and urinalysis are usually performed. If cerebral edema is suspected because of confusion, recurrent vomiting or other symptoms, computed tomography may be performed to assess its severity and to exclude other causes such as stroke.
A meat substitute, also called a meat analogue, approximates certain aesthetic qualities (primarily texture, flavor and appearance) or chemical characteristics of a specific meat. Substitutes are often based on soybeans (such as tofu and tempeh), gluten, or peas. Whole legumes are often used as a protein source in vegetarian dishes, but are not listed here.
== Selected works == Marks, Vincent; Rose, Frank Clifford (1965). Hypoglycaemia. Blackwell. Marks, Vincent; Feldman, Stanley (2006). Panic Nation: Exposing the myths we're told about food and health. Kings Road Publishing. ISBN 978-1-85782-840-5. Marks, Vincent; Richmond, Caroline (2007). Insulin Murders. Taylor & Francis. ISBN 978-1-85315-760-8. Marks, Vincent; Cantor, Thomas; Mesko, Dusan; Pullmann, Rudolf; Nosalova, Gabriela (2012). Differential Diagnosis by Laboratory Medicine: A Quick Reference for Physicians. Springer Science & Business Media. ISBN 978-3-642-55600-5. Hubbard, Ron; Marks, Vincent (2013). Clinical Applications of Monoclonal Antibodies. Springer Science & Business Media. ISBN 978-1-4613-1573-5.
== Therapeutic uses of neohormones == Relaxin has been shown to repair and reverse the symptoms associated with scleroderma (an autoimmune condition affecting connective tissues, blood vessels and internal organs) and fibrosis (thickening, hardening or build up of scar tissue). It also aids in the formation of new blood vessels (angiogenesis). This is also beneficial in wound management and healing. Other potential targets include the use of relaxin within human reproduction, such as in the preparation of the cervix for labour and birth and also as a drug target for breast cancer treatment although much more research is required in this area. Oxytocin is important for many different biological processes including social, maternal and sexual behaviours, pregnancy, milk production, and ejaculation. Agonists and antagonists of oxytocin – development of drugs that can utilise the receptor binding activity of oxytocin is an important therapeutic target as this could be applied to a range of conditions. Oxytocin plays a role in cell proliferation and differentiation in different ways depending on where it is in the body. Understanding the underlying pathways for different localities could help with development of cancer therapies.
Sources: en.wikipedia.org
=== Flammability === In the 1960s there was a lot of interest in fluorocarbons as anesthetics. The research did not produce any anesthetics, but the research included tests on the issue of flammability, and showed that the tested fluorocarbons were not flammable in air in any proportion, though most of the tests were in pure oxygen or pure nitrous oxide (gases of importance in anesthesiology).
=== Alkanes === For linear alkanes, molecular ion peaks are often observed. However, for long chain compounds, the intensity of the molecular ion peaks are often weak. Linear fragments often differ by 14 Da (CH2 = 14). For example, hexane fragmentation patterns. The m/z=57 butyl cation is the base peak, and other most abundant peaks in the spectrum are alkyl carbocations at m/z=15, 29, 43 Da.
Trains are capable of transporting a large number of containers that come from shipping ports. Trains are also used to transport water, cement, grain, steel, wood and coal. They are used because they can carry a large amount and generally have a direct route to the destination. Under the right circumstances, freight transport by rail is more economical and energy efficient than by road, mainly when carried in bulk or over long distances. The main disadvantage of rail freight is its lack of flexibility. For this reason, rail has lost much of the freight business to road transport. Rail freight is often subject to transshipment costs, since it must be transferred from one mode of transportation to another. Practices such as containerization aim at minimizing these costs. When transporting point-to-point bulk loads such as cement or grain, with specialised bulk handling facilities at the rail sidings, the rail mode of transport remains the most convenient and preferred option. Many governments are encouraging shippers to increase their use of rail rather than transport because of trains' lower environmental impact.
== Preservation of microbiology cultures == Bacteria and fungi can be kept short-term (months to about a year, depending) refrigerated, however, cell division and metabolism is not completely arrested and thus is not an optimal option for long-term storage (years) or to preserve cultures genetically or phenotypically, as cell divisions can lead to mutations or sub-culturing can cause phenotypic changes. A preferred option, species-dependent, is cryopreservation. Nematode worms are the only multicellular eukaryotes that have been shown to survive cryopreservation.
Sources: en.wikipedia.org
== Honors == In 2015, Ariely received an honorary doctorate from Erasmus University Rotterdam. He is also a two-time recipient of the William F. O'Dell Award for articles he co-authored. In 2008, Ariely, along with his co-authors, Rebecca Waber, Ziv Carmon, and Baba Shiv, was awarded an Ig Nobel Prize in medicine for their research demonstrating that "high-priced fake medicine is more effective than low-priced fake medicine".
This method was not limited to Douglas; the Irish doctor Francis Hare, who worked in a sanatorium outside London from 1905 onward, also used low-dose apomorphine as a treatment, describing it as "the most useful single drug in the therapeutics of inebriety". He wrote:In (the) sanatorium it is used in three different sets of circumstances: (1) in maniacal or hysterical drunkenness: (2) during the paroxysm of dipsomania, in order to still the craving for alcohol; and (3) in essential insomnia of a special variety... [after giving apomorphine] the patient's mental condition is entirely altered. He may be sober: he is free from the time being from any craving from alcohol. The craving may return, however, and then it is necessary to repeat the injection, it may be several times at intervals of a few hours. These succeeding injections should be quite small, 3 to 6 min. being sufficient. Doses of this size are rarely emetic. There is little facial pallor, a sensation as of the commencement of sea-sickness, perhaps a slight malaise with a sudden subsidence of the craving for alcohol, followed by a light and short doze.He also noted there appeared to be a significant prejudice against the use of apomorphine, both from the associations of its name and doctors being reluctant to give hypodermic injections to alcoholics. In the US, the Harrison Narcotics Tax Act made working with any morphine derivatives extremely hard, despite apomorphine itself not being an opiate.
== History == Use of castor oil as a laxative is attested to in the c. 1550 BC Ebers Papyrus, and it was in use several centuries earlier. Midwifery manuals from the 19th century recommended castor oil and 10 drops of laudanum for relieving "false pains".
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.